On January 26-28, 2021, Dr. Vuong Trieu, CEO of Mateon, will be presenting at TGFβ for Immuno-Oncology Drug Development Summit
On November 3, 2020, Dr. Vuong Trieu, CEO of Mateon, will be presenting at 3rd Meridian Clinical Trials, SAN FRANCISCO, CA
On October 13-15, 2020, Dr. Vuong Trieu, CEO of Mateon, will be presenting “TGF-Β INHIBITORS AS THERAPEUTICS
FOR COVID-19” at BIO Investor Forum Digital
On September 21, 2020, Dr. Vuong Trieu, CEO of Mateon, will be presenting as Webinar “Trabedersen-Drug Development using phosphorothioate antisense platform” at Pharma Forum 2020/ Pharmacology and Toxicology
Blockchain Powered Immuno-Oncology Company Mateon Claims Anti-Malarial Drug Called Artemisinin, Derived from Asian Medicine Can Help Fight Covid-19
In October 2019, Dr. Vuong Trieu, Ph.D., co-founder, President and Chief Executive Officer of Oncotelic will deliver a keynote speech at the Global Congress on Pharmacology and Therapeutics in Paris, France. His presentation will focus on the anti-sense platform for drug development and the Oncotelic pipeline of RNA therapeutics, including OT101.
In October 2019, Oncotelic team will also attend the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. “I look forward to sharing our Phase II clinical data on our first-in class RNA therapeutic for brain tumors as well as our patented Convection-Enhanced Delivery (CED) system with our collaborators and other participating physicians and scientists”, said Dr. Fatih Uckun, MD, PhD the Chief Medical Officer of Oncotelic and Mateon.
Dr. Vuong Trieu, CEO of Mateon/Oncotelic, will be facilitating the roundtable discussions on AI guided development of biologics at 3rd Medicinal Chemistry Strategy Meeting USA West Coast 2019, October 29th, 2019, San Francisco, CA, USA.
Dr. Fatih Uckun – Chief Medical Officer- will be attending Society for NeuroOncology 2019 Annual Meeting Innovation to Overcome Tumor Resistance
